Craig-Hallum analyst Chase Knickerbocker downgraded Alimera Sciences (ALIM) to Hold from Buy with a $5.50 price target after ANI Pharmaceuticals (ANIP) agreed to acquire Alimera for $5.50 per share in cash upfront and one non-tradable contingent value right representing the right to receive up to $0.50 per share upon the achievement of certain net revenue targets.
Don’t Miss TipRanks’ Half Year Sale
- Take advantage of TipRanks Premium for 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ALIM:
- Alimera Sciences Set for Merger with ANI Pharmaceuticals
- Alimera Sciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Alimera Sciences reports Q1 EPS (12c), consensus (6c)
- Alimera Sciences Reports First Quarter 2024 Results
- ALIM Earnings Report this Week: Is It a Buy, Ahead of Earnings?